Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy

Qingdi Quentin Li, Gangduo Wang, Eddie Reed, Lan Huang, Christopher F. Cuff

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Cisplatin is one of the most potent chemotherapeutic agents for the treatment of many types of solid tumours. Nevertheless, it is not the first-line drug for prostate cancer chemotherapy, because prostate tumour cells exhibit intrinsic and acquired resistance to cisplatin. We have previously demonstrated that β-elemene, a novel plant-derived anti-neoplastic with low toxicity, inhibits lung and ovarian carcinoma cell growth in vitro. In the present study, we explored the therapeutically chemosensitizing effect of β-elemene on cisplatin anti-tumour efficacy in androgen-independent prostate cancer cells as well as the underlying mechanism. β-Elemene significantly increased cisplatin cytotoxicity in the androgen-independent prostate carcinoma cell lines DU145 and PC-3. In addition, β-elemene markedly promoted cisplatin-induced apoptotic cell death in both cell lines, as determined by three different apoptosis assays. β-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X L expression, and release of cytochrome c from mitochondria in these cells. Thus, β-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer. Cisplatin combined with β-elemene as a chemosensitizer or adjuvant warrants further study and may be potentially useful as a first-line treatment of androgen-independent prostate carcinomas.

Original languageEnglish (US)
Pages (from-to)868-876
Number of pages9
JournalBasic and Clinical Pharmacology and Toxicology
Volume107
Issue number5
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Chemotherapy
Cisplatin
Prostatic Neoplasms
Drug Therapy
Cells
Androgens
Tumors
Prostate
Caspase 9
Carcinoma
Caspase 3
Neoplasms
Chemical activation
Apoptosis
Caspase 7
elemene
Cell Line
Mitochondria
Cell growth
Cell death

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy. / Li, Qingdi Quentin; Wang, Gangduo; Reed, Eddie; Huang, Lan; Cuff, Christopher F.

In: Basic and Clinical Pharmacology and Toxicology, Vol. 107, No. 5, 11.2010, p. 868-876.

Research output: Contribution to journalArticle

Li, Qingdi Quentin ; Wang, Gangduo ; Reed, Eddie ; Huang, Lan ; Cuff, Christopher F. / Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy. In: Basic and Clinical Pharmacology and Toxicology. 2010 ; Vol. 107, No. 5. pp. 868-876.
@article{5bf03798cd4b48a79033b43edf6ccac2,
title = "Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy",
abstract = "Cisplatin is one of the most potent chemotherapeutic agents for the treatment of many types of solid tumours. Nevertheless, it is not the first-line drug for prostate cancer chemotherapy, because prostate tumour cells exhibit intrinsic and acquired resistance to cisplatin. We have previously demonstrated that β-elemene, a novel plant-derived anti-neoplastic with low toxicity, inhibits lung and ovarian carcinoma cell growth in vitro. In the present study, we explored the therapeutically chemosensitizing effect of β-elemene on cisplatin anti-tumour efficacy in androgen-independent prostate cancer cells as well as the underlying mechanism. β-Elemene significantly increased cisplatin cytotoxicity in the androgen-independent prostate carcinoma cell lines DU145 and PC-3. In addition, β-elemene markedly promoted cisplatin-induced apoptotic cell death in both cell lines, as determined by three different apoptosis assays. β-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X L expression, and release of cytochrome c from mitochondria in these cells. Thus, β-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer. Cisplatin combined with β-elemene as a chemosensitizer or adjuvant warrants further study and may be potentially useful as a first-line treatment of androgen-independent prostate carcinomas.",
author = "Li, {Qingdi Quentin} and Gangduo Wang and Eddie Reed and Lan Huang and Cuff, {Christopher F.}",
year = "2010",
month = "11",
doi = "10.1111/j.1742-7843.2010.00592.x",
language = "English (US)",
volume = "107",
pages = "868--876",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy

AU - Li, Qingdi Quentin

AU - Wang, Gangduo

AU - Reed, Eddie

AU - Huang, Lan

AU - Cuff, Christopher F.

PY - 2010/11

Y1 - 2010/11

N2 - Cisplatin is one of the most potent chemotherapeutic agents for the treatment of many types of solid tumours. Nevertheless, it is not the first-line drug for prostate cancer chemotherapy, because prostate tumour cells exhibit intrinsic and acquired resistance to cisplatin. We have previously demonstrated that β-elemene, a novel plant-derived anti-neoplastic with low toxicity, inhibits lung and ovarian carcinoma cell growth in vitro. In the present study, we explored the therapeutically chemosensitizing effect of β-elemene on cisplatin anti-tumour efficacy in androgen-independent prostate cancer cells as well as the underlying mechanism. β-Elemene significantly increased cisplatin cytotoxicity in the androgen-independent prostate carcinoma cell lines DU145 and PC-3. In addition, β-elemene markedly promoted cisplatin-induced apoptotic cell death in both cell lines, as determined by three different apoptosis assays. β-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X L expression, and release of cytochrome c from mitochondria in these cells. Thus, β-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer. Cisplatin combined with β-elemene as a chemosensitizer or adjuvant warrants further study and may be potentially useful as a first-line treatment of androgen-independent prostate carcinomas.

AB - Cisplatin is one of the most potent chemotherapeutic agents for the treatment of many types of solid tumours. Nevertheless, it is not the first-line drug for prostate cancer chemotherapy, because prostate tumour cells exhibit intrinsic and acquired resistance to cisplatin. We have previously demonstrated that β-elemene, a novel plant-derived anti-neoplastic with low toxicity, inhibits lung and ovarian carcinoma cell growth in vitro. In the present study, we explored the therapeutically chemosensitizing effect of β-elemene on cisplatin anti-tumour efficacy in androgen-independent prostate cancer cells as well as the underlying mechanism. β-Elemene significantly increased cisplatin cytotoxicity in the androgen-independent prostate carcinoma cell lines DU145 and PC-3. In addition, β-elemene markedly promoted cisplatin-induced apoptotic cell death in both cell lines, as determined by three different apoptosis assays. β-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X L expression, and release of cytochrome c from mitochondria in these cells. Thus, β-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer. Cisplatin combined with β-elemene as a chemosensitizer or adjuvant warrants further study and may be potentially useful as a first-line treatment of androgen-independent prostate carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=78649537934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649537934&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2010.00592.x

DO - 10.1111/j.1742-7843.2010.00592.x

M3 - Article

VL - 107

SP - 868

EP - 876

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 5

ER -